GLP-1s linked to a nasty side effect in nails: study
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"GLP-1s linked to a nasty side effect in nails: study" is generating significant coverage in the Health category, with 1 articles from 1 distinct sources tracked by PULSE so far.
Outlets currently covering the story include New York Post. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 1h ago.
Quick answers
Why is "GLP-1s linked to a nasty side effect in nails: study" trending?
Because 1 independent news sources published 1 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (1)
- GLP-1s linked to a nasty side effect in nails: study New York Post · 3h ago
Topics
Related trends
The evidence suggesting GLP-1s can curb drug and alcohol cravings
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Some who take GLP-1s are suffering serious side effects, but it's unclear how often
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
New study suggests possible connection between GLP-1s and hair loss in men
Recent studies and reports indicate surprising physical side effects among users of popular GLP-1 weight-loss medications.
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'
GLP-1 medications are shifting from clinical obesity treatments for patients to lifestyle products for customers, amid a surge in oral pill options.
McDonald's reveals major changes coming to menus, including a shift due to GLP-1s
McDonald's announces massive investments in menu updates, artificial intelligence, and PlayPlaces amid rising customer cost concerns.